相关实验视频

Updated: Jan 13, 2026

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

在向治疗时代,为CLL提供一线治疗

Matthew S Davids¹, Stephan Stilgenbauer², Constantine S Tam³

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. matthew_davids@dfci.harvard.edu.

Blood cancer journal

|January 8, 2026

概括

向治疗,包括布鲁顿的氨酸激酶 (BTK) 抑制剂和BCL2抑制剂,现在取代了化疗免疫治疗作为慢性淋巴细胞白血病 (CLL) 的标准治疗方法. 治疗选择涉及患者特定因素和分子疾病特征.

科学领域:

在瘤学瘤学.
血液学血液学血液学
药理学药理学是指药理学的学科.

背景情况:

慢性淋巴细胞白血病 (CLL) 的治疗模式自布鲁顿氨酸激酶 (BTK) 抑制剂的引入以来发生了重大变化.
化疗免疫疗法不再是大多数以前未经治疗的CLL患者的标准护理,现在普遍推的向药物.

研究的目的:

审查支持CLL一线向治疗的关键受控试验数据.
讨论影响选择适当的向治疗方案的因素.
探索基于最小残留疾病的个性化CLL治疗的未来方向.

主要方法:

对一线CLL向治疗的关键受控临床试验数据的审查.
对CLL管理的国家指南 (2023-2025) 的分析.
评估影响治疗决策的因素,包括分子标志物和患者的并发症.

主要成果:

向治疗,包括BTK抑制剂 (ibrutinib,zanubrutinib,acalabrutinib) 和BCL2抑制剂 (venetoclax) 组合,是CLL的主要一线选择.
治疗选择以分子特征 (例如,del[17p]/TP53,IGHV状态),并发症,药物和患者偏好为指导.
化学免疫疗法只适用于特殊的CLL病例.

结论:

针对性治疗的普遍采用代表了CLL管理的重大进步.
个性化治疗选择对于优化CLL的结果至关重要.
目前正在进行的研究和最小残留疾病监测有望进一步完善CLL治疗策略.

更多相关视频

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...